此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

IBI3001 在患有不可切除、局部晚期或转移性实体瘤的参与者中的应用

2026年9月22日 更新者:Fortvita Biologics (USA)Inc.

IBI3001 在患有不可切除、局部晚期或转移性实体瘤受试者中的 1/2 期研究

This is a Phase 1 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. The purpose of this study is to identify the MTD/RP2D of IBI3001, and to explore the preliminary efficacy of IBI3001.

研究概览

地位

招聘中

干预/治疗

研究类型

介入性

注册 (估计的)

250

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Anhui
      • Hefei、Anhui、中国、230022
        • 招聘中
        • The First Affiliated Hospital of Anhui Medical University
        • 接触:
    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100021
        • 招聘中
        • Cancer Hospital, Chinese Academy of Medical Sciences
        • 接触:
      • Beijing、Beijing Municipality、中国、100853
        • 招聘中
        • Chinese People's Liberation Army General Hospital
        • 接触:
    • Fujian
      • Fuzhou、Fujian、中国、350014
      • Fuzhou、Fujian、中国、350005
        • 招聘中
        • First Affiliated Hospital, Fujian Medical University
        • 接触:
    • Guangxi
      • Nanning、Guangxi、中国、530021
        • 招聘中
        • The Affiliated Tumor Hospital of Guangxi Medical University
        • 接触:
    • Heilongjiang
      • Harbin、Heilongjiang、中国、150081
    • Henan
      • Anyang、Henan、中国、455100
      • Luoyang、Henan、中国、471003
        • 招聘中
        • The First Affiliated Hospital of Henan University of Science and Technology
        • 接触:
      • Zhengzhou、Henan、中国、450008
      • Zhengzhou、Henan、中国、450052
        • 招聘中
        • The First Affiliated Hospital of Zhengzhou University
        • 接触:
    • Hubei
      • Wuhan、Hubei、中国、430022
        • 招聘中
        • Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • 接触:
    • Hunan
      • Changsha、Hunan、中国、410008
        • 招聘中
        • Xiangya Hospital, Central South University
        • 接触:
    • Jiangsu
      • Nanjing、Jiangsu、中国、210008
        • 招聘中
        • Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
        • 接触:
      • Nanjing、Jiangsu、中国、210029
        • 招聘中
        • Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University)
        • 接触:
    • Jiangxi
      • Nanchang、Jiangxi、中国、330029
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200120
        • 招聘中
        • Shanghai East Hospital, Tongji University School of Medicine
        • 接触:
    • Sichuan
      • Chengdu、Sichuan、中国、610041
      • Chengdu、Sichuan、中国、610041
    • Zhejiang
      • Hangzhou、Zhejiang、中国、310022
      • Hangzhou、Zhejiang、中国、310003
        • 招聘中
        • The First Affiliated Hospital, Zhejiang University School of Medicine
        • 接触:
    • New South Wales
      • Wollongong、New South Wales、澳大利亚、2500
    • South Australia
      • Adelaide、South Australia、澳大利亚、5000
    • California
      • Los Angeles、California、美国、90025
    • New Jersey
      • East Brunswick、New Jersey、美国、08816
    • Texas
      • Dallas、Texas、美国、75039
    • Virginia
      • Fairfax、Virginia、美国、22031
        • 主动,不招人
        • Virginia Cancer Specialists

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  1. Male or female participants ≥ 18 years old;
  2. Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
  3. Has an anticipated life expectancy of ≥ 12 weeks;
  4. Adequate bone marrow and organ function:
  5. At least 1 evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. for dose escalation , and 1 measurable lesion for dose expansion.
  6. Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available; participants who refuse standard therapy, or are able to suspend standard therapy without major risks.

Key Exclusion Criteria:

  1. Progressed or refractory to an ADC that consists of an Exatecan derivative that is a topoisomerase I inhibitor or intolerable with an ADC that consists of Exatecan;
  2. Plan to receive other antitumor therapy during the study excluding palliative radiotherapy for the purpose of symptom (like pain) relief that must also not have an impact on tumor assessment throughout the study;
  3. Pyloric obstruction and/or persistent recurrent vomiting (≥ 3 times in 24 hours);
  4. Gastrointestinal perforation and/or fistula within 6 months prior to first administration of the study drug, and not recovered after surgical treatment;
  5. Known symptomatic central nervous system (CNS) metastases.
  6. History of pneumonia requiring corticosteroids therapy, or history of clinically significant lung diseases; Uncontrolled diseases;
  7. History of endotracheal or gastrointestinal stent implantation;
  8. Ascites, pleural effusion, or pericardial effusion with symptoms and requiring intervention;
  9. Esophageal or gastric varices requiring immediate intervention;
  10. Not eligible to participate in this study at the discretion of the investigator;
  11. Do not have adequate treatment washout period before study drug administration. -

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:开放标签:IBI3001单一疗法

The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study.

IBI3001 is proposed to be administered by intravenous infusion (IV)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of subjects with adverse events
大体时间:24 months

Occurrence and severity of adverse events (AEs), with severity determined by NCI CTCAE v5.0 criteria

24 months
Number of subjects with clinically significant changes in physical examination results
大体时间:24 months

Clinically significant abnormal physical examination findings reported by the investigator.

24 months
Number of subjects with clinically significant changes in vital signs
大体时间:24 months

Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure

24 months
MTD or RP2D of IBI3001 Number of subjects with dose-limiting toxicities (DLTs)
大体时间:24 months

Dose limiting toxicity (DLT) to establish MTD or RP2D

24 months

次要结果测量

结果测量
措施说明
大体时间
Plasma concentration (Cmax) of IBI3001
大体时间:24 months

Plasma concentration of IBI3001 for single and multiple doses.

24 months
Area under the curve (AUC) of IBI3001
大体时间:24 months

AUC of IBI3001 for single and multiple doses

24 months
Time to maximum concentration (Tmax) of IBI3001
大体时间:24 months

Tmax of IBI3001 for single and multiple doses.

24 months
Clearance (CL) of IBI3001
大体时间:24 months

Clearance of IBI3001 from the plasma

24 months
Volume of distribution (V) of IBI3001
大体时间:24 months

Apparent volume of distribution of IBI3001

24 months
Half-life (T1/2) of IBI3001
大体时间:24 months

T1/2 of IBI3001 for single and multiple doses

24 months
Immunogenicity of IBI3001
大体时间:24 months

Incidence of anti-drug (IBI3001) antibody

24 months
Objective response rate (ORR)
大体时间:24 months

ORR as evaluated per the RECIST v1.1 criteria

24 months
Duration of response (DoR)
大体时间:24 months

DoR as evaluated per the RECIST v1.1 criteria

24 months
Disease control rate (DCR)
大体时间:24 months

DCR as evaluated per the RECIST v1.1 criteria

24 months
Time to response (TTR)
大体时间:24 months

TTR as evaluated per the RECIST v1.1 criteria

24 months
Progression free survival (PFS)
大体时间:24 months

PFS as evaluated per the RECIST v1.1 criteria

24 months
Overall survival (OS)
大体时间:24 months

Overall survival.

24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年1月10日

初级完成 (估计的)

2026年12月31日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2024年4月1日

首先提交符合 QC 标准的

2024年4月1日

首次发布 (实际的)

2024年4月5日

研究记录更新

最后更新发布 (实际的)

2026年9月25日

上次提交的符合 QC 标准的更新

2026年9月22日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • CIBI3001A101

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅